Sutro Biopharma STRO
NASDAQ STRO
$11.59 +0.33 (+2.93%)
As of: Oct 20, 2026 · 3:06 PM EDT

Sutro Biopharma (STRO) Restructuring Costs (2025 - 2026)

Updated

Sutro Biopharma (STRO) recorded Restructuring Costs of $201,000 in Q2 2026, down 98.9% from $18.42 million a year earlier.

Analysis

Sutro Biopharma (STRO) Restructuring Costs (2025 - 2026) Analysis & Trends

On a TTM basis, Sutro Biopharma's Restructuring Costs came in at $32.57 million as of Jun 30, 2026, down 17.5% year-over-year; for FY2025, it came in at $53.42 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,145.25 Bn 1,113.84 Bn 19.71 Bn
2 Johnson & Johnson 623.54 Bn 542.07 Bn 17.26 Bn
3 AbbVie 511.36 Bn 484.47 Bn 12.70 Bn
4 Merck 366.62 Bn 321.00 Bn 12.21 Bn
5 Novartis Ag 297.46 Bn 261.45 Bn 11.24 Bn
6 Astrazeneca 261.61 Bn 235.29 Bn 12.86 Bn
7 Amgen 235.29 Bn 190.69 Bn 7.24 Bn
8 Gilead Sciences 193.89 Bn 168.09 Bn 6.22 Bn
9 Pfizer 172.02 Bn 118.67 Bn 10.94 Bn
10 Sutro Biopharma 191.90 Mn -486.60 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 201,000.00
Dec 31, 2025 4.39 Mn
Sep 30, 2025 9.56 Mn
Jun 30, 2025 18.42 Mn
Mar 31, 2025 21.04 Mn
API Access

Sutro Biopharma Restructuring Costs API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=restructuring-costs&ticker=STRO&period=max&api_key=YOUR_API_KEY